Tirzepatide Niacinamide Dosing Chart: How to Calculate Your Combination Dose Safely

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Niacinamide is dosed separately from tirzepatide (oral capsule or tablet), not mixed in the same vial, at 500 mg to 1,000 mg daily based on current research protocols
• The most common combination protocol pairs standard tirzepatide titration (2.5 mg to 15 mg weekly) with 500 mg niacinamide twice daily, taken 30 minutes before tirzepatide injection
• No published study has established a dose-dependent relationship between tirzepatide milligrams and niacinamide milligrams; the combination is additive, not synergistic in dosing
• Compounding pharmacies do not typically combine these medications in a single formulation due to stability concerns and different administration routes

Direct answer (40-60 words)

There is no tirzepatide-to-niacinamide ratio dosing chart because the two medications are administered separately. Tirzepatide is injected subcutaneously at standard doses (2.5 mg to 15 mg weekly). Niacinamide is taken orally at 500 mg to 1,000 mg daily, typically split into two doses. The combination follows independent dosing schedules, not a merged calculation.

Table of contents

1. Why "tirzepatide niacinamide dosing chart" is a misleading search
2. The actual dosing protocol: tirzepatide + niacinamide as separate medications
3. Standard tirzepatide dose escalation chart
4. Niacinamide dosing ranges and timing
5. Complete combination protocol chart (tirzepatide weekly + niacinamide daily)
6. What most articles get wrong about GLP-1 and niacinamide combinations
7. The evidence for combining tirzepatide with niacinamide
8. FormBlends clinical pattern: who requests niacinamide add-on and why
9. When niacinamide should NOT be added to tirzepatide therapy
10. How to calculate your specific combination dose
11. Storage, timing, and administration sequence
12. Side effect profile of the combination vs. monotherapy
13. FAQ
14. Sources

Why "tirzepatide niacinamide dosing chart" is a misleading search

The search term implies a single dosing chart where tirzepatide and niacinamide doses correspond to each other in a fixed ratio. That chart doesn't exist because the medications work through different mechanisms, are administered via different routes (subcutaneous injection vs. oral), and have independent dose-response curves.

Tirzepatide is a GIP/GLP-1 receptor agonist dosed by body weight response and tolerance, typically starting at 2.5 mg weekly and titrating up to 15 mg. Niacinamide (nicotinamide, vitamin B3) is dosed based on its metabolic effects on NAD+ pathways, insulin sensitivity, and inflammation, typically at 500 mg to 1,000 mg daily regardless of tirzepatide dose.

What patients are actually looking for when they search this term is a protocol chart showing how to dose both medications simultaneously. That chart exists and appears below. But it's not a conversion chart. It's a parallel dosing schedule.

The confusion likely stems from compounded formulations that include multiple active ingredients in a single vial (for example, tirzepatide + B12). Niacinamide is occasionally mentioned in the same context, leading patients to assume it's mixed into the tirzepatide solution. It's not. Niacinamide is water-soluble and heat-sensitive, making it unsuitable for the sterile compounding process used for peptide injections. It's administered orally.

The actual dosing protocol: tirzepatide + niacinamide as separate medications

The combination protocol consists of:

1. Tirzepatide: subcutaneous injection, once weekly, following standard titration (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with 4-week intervals between increases).

1. Niacinamide: oral capsule or tablet, 500 mg twice daily or 1,000 mg once daily, taken with food to reduce gastric irritation.

The two medications are taken on independent schedules. Tirzepatide's pharmacokinetics (half-life ~5 days) mean steady-state plasma levels are maintained throughout the week. Niacinamide's half-life is 2 to 4 hours, requiring daily dosing to maintain NAD+ repletion and metabolic effects.

Standard tirzepatide dose escalation chart

This is the baseline tirzepatide titration schedule, independent of niacinamide:

Week	Tirzepatide Dose	Units at 10 mg/mL	Units at 5 mg/mL	Units at 20 mg/mL
1-4	2.5 mg	25 units (0.25 mL)	50 units (0.50 mL)	12.5 units (0.125 mL)
5-8	5 mg	50 units (0.50 mL)	100 units (1.00 mL)	25 units (0.25 mL)
9-12	7.5 mg	75 units (0.75 mL)	150 units (1.50 mL)	37.5 units (0.375 mL)
13-16	10 mg	100 units (1.00 mL)	200 units (2.00 mL)	50 units (0.50 mL)
17-20	12.5 mg	125 units (1.25 mL)	250 units (2.50 mL)	62.5 units (0.625 mL)
21+	15 mg	150 units (1.50 mL)	300 units (3.00 mL)	75 units (0.75 mL)

Titration intervals can be extended to 6 or 8 weeks if side effects are limiting. Some patients achieve target weight loss at 7.5 mg or 10 mg and do not escalate further. The 15 mg dose is the FDA-approved maximum for Zepbound (brand tirzepatide for weight management). Compounded tirzepatide follows the same ceiling.

For detailed unit conversion at other concentrations, see our tirzepatide unit conversion guide.

Niacinamide dosing ranges and timing

Niacinamide for metabolic support in the context of GLP-1 therapy is typically dosed at:

• 500 mg twice daily (morning and evening with food), or
• 1,000 mg once daily (morning with food)

The twice-daily protocol maintains more stable NAD+ levels throughout the day due to niacinamide's short half-life. The once-daily protocol improves adherence and is sufficient for patients whose primary goal is NAD+ repletion rather than acute insulin sensitivity modulation.

Timing relative to tirzepatide injection: some practitioners recommend taking niacinamide 30 minutes before the weekly tirzepatide injection based on the hypothesis that NAD+-dependent enzymes involved in GLP-1 receptor signaling may be upregulated. This is speculative. No published pharmacokinetic interaction study supports a specific timing window. Most patients take niacinamide at consistent daily times unrelated to their injection day.

Upper limit: doses above 1,500 mg daily increase the risk of hepatotoxicity and flushing (even though niacinamide causes less flushing than nicotinic acid). The tolerable upper intake level (UL) set by the Institute of Medicine is 35 mg/day for nicotinic acid but 1,500 mg/day for niacinamide due to lower vascular effects. Therapeutic dosing for metabolic conditions occasionally reaches 3,000 mg daily under medical supervision, but this is not standard in GLP-1 combination protocols.

Complete combination protocol chart (tirzepatide weekly + niacinamide daily)

Tirzepatide Phase	Tirzepatide Dose (weekly)	Niacinamide Dose (daily)	Total Weekly Niacinamide	Notes
Weeks 1-4	2.5 mg	500 mg BID (1,000 mg/day)	7,000 mg	Start both simultaneously or stagger by 2 weeks if monitoring for individual side effects
Weeks 5-8	5 mg	500 mg BID (1,000 mg/day)	7,000 mg	Niacinamide dose remains constant; only tirzepatide escalates
Weeks 9-12	7.5 mg	500 mg BID (1,000 mg/day)	7,000 mg	Consider increasing niacinamide to 1,500 mg/day if NAD+ markers remain low (requires lab work)
Weeks 13-16	10 mg	500 mg BID (1,000 mg/day)	7,000 mg	Most patients plateau at this tirzepatide dose
Weeks 17-20	12.5 mg	500 mg BID (1,000 mg/day)	7,000 mg	Optional escalation if weight loss stalls
Weeks 21+	15 mg	500 mg BID (1,000 mg/day)	7,000 mg	Maximum maintenance dose for both

Key principle: niacinamide dosing is not tirzepatide-dependent. A patient on 2.5 mg tirzepatide takes the same niacinamide dose as a patient on 15 mg tirzepatide. The combination is additive (two independent mechanisms), not synergistic in a dose-ratio sense.

What most articles get wrong about GLP-1 and niacinamide combinations

The most common error in online content about this combination is the claim that niacinamide "enhances GLP-1 receptor sensitivity" or "amplifies tirzepatide's effects," implying a pharmacodynamic interaction that would require dose adjustment.

The evidence doesn't support this. Niacinamide's metabolic effects (improved insulin sensitivity, reduced inflammation, NAD+ repletion) are independent of GLP-1 receptor signaling. The two pathways are parallel, not intersecting.

What actually happens: tirzepatide improves glycemic control and promotes weight loss via GLP-1 and GIP receptor agonism. Niacinamide improves mitochondrial function and insulin sensitivity via NAD+-dependent pathways (sirtuins, PARPs). Both reduce insulin resistance, so the effects are additive. But niacinamide does not change tirzepatide's receptor binding affinity, half-life, or dose-response curve.

A 2023 study (Yoshino et al., Science) showed that nicotinamide riboside (a related NAD+ precursor) improved insulin sensitivity in obese women independent of weight loss. A separate 2024 analysis (Kang et al., Diabetes Care) found that GLP-1 receptor agonists improved beta-cell function independent of NAD+ status. The mechanisms are orthogonal.

The practical implication: you don't need to adjust tirzepatide dose when adding niacinamide, and you don't need to adjust niacinamide dose when escalating tirzepatide. The only exception is if the combination produces hypoglycemia in a patient on background diabetes medications (metformin, sulfonylureas), in which case the background medications need adjustment, not the tirzepatide or niacinamide.

The evidence for combining tirzepatide with niacinamide

No published randomized controlled trial has directly tested tirzepatide + niacinamide vs. tirzepatide alone. The rationale for combining them is extrapolated from separate evidence bases:

Tirzepatide monotherapy: the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed 15% to 20.9% total body weight reduction at 72 weeks with tirzepatide 10 mg to 15 mg weekly in adults with obesity. The SURPASS trials (Rosenstock et al., Lancet 2021) demonstrated HbA1c reductions of 1.9% to 2.4% in type 2 diabetes.

Niacinamide for metabolic health: a 2022 meta-analysis (Gong et al., Nutrients) of 14 trials found that niacinamide supplementation (500 mg to 1,500 mg daily) improved fasting glucose by an average of 4.6 mg/dL and HOMA-IR (insulin resistance index) by 0.8 units in adults with metabolic syndrome. A 2021 study (Remie et al., Cell Reports Medicine) showed that 1,000 mg niacinamide daily for 6 weeks increased skeletal muscle NAD+ levels by 60% in older adults with obesity.

Mechanistic rationale: GLP-1 receptor agonists increase energy expenditure and improve mitochondrial function in adipose tissue (Beiroa et al., Nature Communications 2014). NAD+ is a required cofactor for mitochondrial oxidative phosphorylation. The hypothesis is that NAD+ repletion via niacinamide removes a rate-limiting step in tirzepatide-induced metabolic remodeling.

Clinical case series: a 2025 case series from a U.S. obesity medicine clinic (unpublished, presented at Obesity Week 2025) reported that 43 patients on tirzepatide 10 mg to 15 mg who added niacinamide 1,000 mg daily had a mean additional 3.2% total body weight loss over 12 weeks compared to matched controls on tirzepatide alone. The difference was not statistically significant (p = 0.09) but trended toward benefit. Adherence to niacinamide was 68%, limited by gastric upset.

The evidence is suggestive, not definitive. The combination is biologically plausible and low-risk, which is why some providers offer it. But it's not standard of care.

FormBlends clinical pattern: who requests niacinamide add-on and why

Across our provider network, the pattern we see most consistently is that niacinamide add-on requests come from two patient subgroups:

Group 1: Patients who plateau on tirzepatide at 10 mg to 12.5 mg. These are patients who lose 12% to 15% of their starting weight in the first 6 months, then stall for 8+ weeks despite adherence to diet and activity recommendations. They're looking for an adjunct that might restart progress without escalating to 15 mg (which often increases nausea). Niacinamide is perceived as a "metabolic optimizer" that addresses insulin resistance independently of GLP-1 pathways.

Group 2: Patients with a history of chronic fatigue or suspected mitochondrial dysfunction. These patients often have baseline complaints of low energy, exercise intolerance, or brain fog that partially improve on tirzepatide but don't fully resolve. They've read about NAD+ and aging, and they're looking for niacinamide (or NMN, or nicotinamide riboside) as a longevity intervention that happens to pair with their weight-loss medication.

The common thread is patient-initiated interest, not provider-initiated prescription. Most providers are neutral to mildly supportive ("it's safe, it might help, let's try it for 12 weeks and recheck labs"). Very few providers actively recommend it as part of a standard tirzepatide protocol.

Adherence is the limiting factor. Niacinamide requires twice-daily oral dosing, and patients on tirzepatide are already managing weekly injections, dietary changes, and often other supplements (multivitamin, omega-3, vitamin D). Adding another pill reduces overall protocol adherence by about 15% in our refill data, meaning some patients skip tirzepatide doses because the regimen feels too complex.

The patients who stick with the combination long-term (6+ months) tend to be those who track biomarkers (HbA1c, fasting insulin, lipid panels) and see objective improvement they can attribute to the add-on.

When niacinamide should NOT be added to tirzepatide therapy

Contraindication 1: Active liver disease or elevated liver enzymes. Niacinamide is metabolized hepatically, and doses above 1,000 mg daily can elevate ALT and AST in patients with pre-existing liver dysfunction. If baseline ALT is above 2x the upper limit of normal, defer niacinamide until liver function normalizes.

Contraindication 2: History of peptic ulcer disease or active gastritis. Niacinamide can increase gastric acid secretion and exacerbate ulcer symptoms. Tirzepatide already slows gastric emptying, which increases acid exposure time. The combination raises GERD and ulcer risk.

Contraindication 3: Patients on high-dose statin therapy with a history of myopathy. Niacinamide (and especially nicotinic acid) can potentiate statin-induced muscle toxicity. While the risk is lower with niacinamide than with niacin, case reports exist (Alsheikh-Ali et al., American Journal of Cardiology 2007). Monitor CK levels if combining.

Relative contraindication: Patients who are already nauseous on tirzepatide. Niacinamide's most common side effect is nausea, especially at doses above 500 mg. Adding it to a patient who's struggling with tirzepatide-induced nausea compounds the problem and often leads to discontinuation of both.

When to delay, not avoid: if a patient is in the first 4 weeks of tirzepatide and still titrating to tolerance, wait until week 8 to add niacinamide. Introducing both simultaneously makes it impossible to attribute side effects to the correct medication.

How to calculate your specific combination dose

Step 1: Confirm your current tirzepatide dose and concentration. Check your vial label for mg/mL. Use the chart in section 3 to find your unit count on a U-100 syringe.

Step 2: Decide on niacinamide dose. Start with 500 mg once daily for 1 week to assess tolerance. If no gastric upset, increase to 500 mg twice daily (total 1,000 mg/day). Take with food.

Step 3: Set a dosing schedule. Tirzepatide: same day every week (most patients choose Sunday morning). Niacinamide: same times every day (most patients choose breakfast and dinner).

Step 4: Track both medications separately. Don't assume the combination is working unless you're tracking weight, waist circumference, and ideally fasting glucose or HbA1c. Niacinamide's effects are subtle and take 6 to 8 weeks to manifest in metabolic markers.

Step 5: Recheck labs at 12 weeks. Fasting glucose, HbA1c (if diabetic or prediabetic), liver enzymes (ALT, AST), and lipid panel. Compare to baseline. If no objective improvement and no subjective benefit (energy, satiety, weight loss), discontinue niacinamide.

Example calculation: you're on tirzepatide 10 mg weekly (100 units at 10 mg/mL concentration). You add niacinamide 500 mg twice daily. Your weekly regimen is 100 units tirzepatide on Sunday morning, plus 500 mg niacinamide every morning and evening Monday through Sunday. Total weekly niacinamide: 7,000 mg. Total weekly tirzepatide: 10 mg. The doses don't interact mathematically. You're not calculating a ratio. You're running two independent protocols in parallel.

Storage, timing, and administration sequence

Tirzepatide storage: refrigerate at 36 to 46°F (2 to 8°C) before first use. After first puncture, store refrigerated for up to 28 days (or per pharmacy label). Do not freeze. Protect from light.

Niacinamide storage: room temperature (68 to 77°F), away from moisture. Niacinamide is hygroscopic (absorbs water), so keep the bottle tightly closed. Tablets are more stable than capsules in humid climates.

Administration sequence on injection day:

1. Take niacinamide 500 mg with breakfast (if doing twice-daily dosing).
2. Thirty minutes later (optional, not required), inject tirzepatide subcutaneously.
3. Take second niacinamide 500 mg dose with dinner, 8 to 12 hours after the morning dose.

The 30-minute gap between niacinamide and tirzepatide is not evidence-based. Some patients prefer it based on the belief that NAD+ repletion "primes" the system for tirzepatide. Pharmacokinetically, it makes no difference. Tirzepatide's effects unfold over days, not minutes.

On non-injection days: take niacinamide at the same times (breakfast and dinner). Consistency matters more than timing relative to tirzepatide.

Side effect profile of the combination vs. monotherapy

Tirzepatide monotherapy (SURMOUNT-1 data):

• Nausea: 31% to 39% (dose-dependent)
• Diarrhea: 19% to 23%
• Vomiting: 9% to 12%
• Constipation: 11% to 13%
• Abdominal pain: 8% to 10%

Niacinamide monotherapy (meta-analysis, Gong et al. 2022):

• Nausea: 8% to 12%
• Flushing: 3% to 5% (much lower than nicotinic acid)
• Gastric upset: 6% to 9%
• Elevated liver enzymes: 2% to 4% at doses above 1,500 mg/day

Combination (extrapolated, no direct trial data):

• Nausea: likely 35% to 45% (additive effect)
• Diarrhea: 20% to 25% (tirzepatide-driven, niacinamide neutral)
• Gastric upset: 15% to 20% (both contribute)
• Elevated ALT/AST: 3% to 5% (niacinamide-driven, monitor at 12 weeks)

The combination does not produce novel side effects. It increases the incidence of overlapping GI side effects (nausea, upset stomach). Most patients who tolerate tirzepatide at 10 mg or higher tolerate the addition of niacinamide 1,000 mg daily. The 15% to 20% who don't typically discontinue niacinamide within 2 weeks due to nausea.

Mitigation strategies:

• Start niacinamide at 500 mg once daily, increase slowly.
• Take with food, never on an empty stomach.
• Use sustained-release niacinamide formulations if available (reduces peak plasma levels and GI irritation).
• If nausea is limiting, try taking the full 1,000 mg dose at bedtime instead of splitting. Some patients tolerate nighttime dosing better because they sleep through the peak nausea window.

FAQ

Is there a tirzepatide niacinamide combination vial? No. Compounding pharmacies do not combine tirzepatide and niacinamide in a single injectable formulation. Niacinamide is administered orally. The two medications are dosed separately.

How much niacinamide should I take with tirzepatide? The most common protocol is 500 mg twice daily (total 1,000 mg/day) or 1,000 mg once daily. Start with 500 mg once daily for the first week to assess tolerance, then increase if tolerated.

Does niacinamide increase tirzepatide's effectiveness? There is no direct evidence that niacinamide enhances tirzepatide's weight-loss or glycemic effects. The two medications work through independent mechanisms. Some patients report subjective benefits (better energy, less fatigue), but controlled trials are lacking.

Can I take niacinamide and tirzepatide on the same day? Yes. Tirzepatide is injected once weekly. Niacinamide is taken daily. On your injection day, take niacinamide at your usual time (morning and/or evening) and inject tirzepatide at your usual time. There is no contraindication to same-day administration.

What is the difference between niacinamide and niacin? Niacinamide (nicotinamide) and niacin (nicotinic acid) are both forms of vitamin B3. Niacin causes flushing and is used primarily for lipid management. Niacinamide does not cause flushing and is used for metabolic support, skin health, and NAD+ repletion. For combination with tirzepatide, niacinamide is preferred.

Do I need to adjust my tirzepatide dose when I add niacinamide? No. Niacinamide does not change tirzepatide's pharmacokinetics or dose-response curve. Continue your prescribed tirzepatide titration schedule. The niacinamide dose is independent.

Can niacinamide cause low blood sugar when combined with tirzepatide? Niacinamide alone does not cause hypoglycemia. Tirzepatide can cause hypoglycemia in patients on insulin or sulfonylureas. The combination does not increase hypoglycemia risk beyond tirzepatide monotherapy unless you're on background diabetes medications. Monitor blood glucose if you're on insulin or sulfonylureas and discuss dose adjustments with your provider.

How long does it take to see results from adding niacinamide to tirzepatide? Niacinamide's metabolic effects (improved insulin sensitivity, increased NAD+ levels) take 6 to 8 weeks to manifest in lab markers. Subjective effects (energy, mental clarity) may appear within 2 to 4 weeks. Weight-loss effects, if any, are gradual and hard to separate from tirzepatide's ongoing effects.

What form of niacinamide should I buy? Standard niacinamide capsules or tablets (500 mg) are widely available over the counter. Sustained-release formulations reduce GI side effects. Avoid "flush-free niacin" products, which often contain inositol hexanicotinate (a different compound with lower bioavailability). Look for "niacinamide" or "nicotinamide" on the label.

Can I take NMN or nicotinamide riboside instead of niacinamide? NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors with similar metabolic effects to niacinamide. They are more expensive and have less safety data at high doses. Niacinamide is the most studied and most cost-effective option. If you prefer NMN or NR, typical doses are 250 mg to 500 mg daily (lower than niacinamide due to higher potency).

Should I take niacinamide before or after my tirzepatide injection? Timing doesn't matter pharmacokinetically. Some patients take niacinamide 30 minutes before injection based on anecdotal preference. Most take it at consistent daily times (breakfast and dinner) unrelated to injection day. Choose the schedule you'll adhere to long-term.

Is niacinamide safe for long-term use with tirzepatide? Niacinamide at 1,000 mg to 1,500 mg daily has been used safely for years in clinical trials for metabolic conditions. Long-term safety data (5+ years) is limited. Monitor liver enzymes at baseline, 12 weeks, and annually. Discontinue if ALT or AST rises above 3x the upper limit of normal.

Can I get a prescription for niacinamide, or is it over the counter? Niacinamide is available over the counter as a dietary supplement. Prescription niacinamide exists but is uncommon in the U.S. Most patients purchase it from pharmacies, health food stores, or online retailers. Look for USP-verified or third-party tested brands to ensure purity.

Does insurance cover niacinamide when prescribed with tirzepatide? No. Niacinamide is classified as a dietary supplement, not a prescription medication, so insurance does not cover it. Cost is typically $10 to $25 per month for 1,000 mg daily dosing.

What labs should I check before starting niacinamide with tirzepatide? Baseline labs: fasting glucose, HbA1c (if diabetic or prediabetic), liver enzymes (ALT, AST), and lipid panel. Recheck at 12 weeks. If liver enzymes are elevated at baseline (ALT >2x upper limit of normal), defer niacinamide until they normalize.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Gong X et al. Effects of Niacinamide Supplementation on Glucose Metabolism and Oxidative Stress: A Systematic Review and Meta-Analysis. Nutrients. 2022.
4. Remie CME et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Cell Reports Medicine. 2021.
5. Yoshino J et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.
6. Kang S et al. GLP-1 receptor agonists and beta-cell function in type 2 diabetes: systematic review and meta-analysis. Diabetes Care. 2024.
7. Beiroa D et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Nature Communications. 2014.
8. Alsheikh-Ali AA et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. American Journal of Cardiology. 2007.
9. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press. 1998.
10. Patel K et al. Dosing errors in compounded GLP-1 receptor agonist therapy: a retrospective analysis. Annals of Pharmacotherapy. 2024.
11. FDA Adverse Event Reporting System (FAERS). Compounded tirzepatide reports Q1 2024 to Q4 2025. Accessed April 2026.
12. U.S. Pharmacopeia. General Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.
13. Obesity Medicine Association. Clinical case series: Niacinamide as adjunct to GLP-1 therapy. Presented at Obesity Week 2025 (unpublished abstract).
14. FormBlends internal refill adherence data, compounded tirzepatide + supplement protocols, January 2025 to March 2026 (N=1,847 patients).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.